I am very happy to share our article on the characterisation of the MCM/FLExDUX4 mice. We highlighted several changes that could be used as markers of therapeutic efficacy and developed a force test that reflects the movements made in everyday life. #FSHD
https://t.co/MuXgd4J5ST
Virginie Mariot has presented our work on short and long term efficacy of an AAV-shDUX4 in a DUX4 mouse model @FSHDSociety IRC conference in Denver. A lot of very interesting discussions. #FSHD@DNP_ICH
FSHD UK founder Rajeshri Badiani recently made waves at the IRC with a captivating presentation - covering our history and her tireless endeavours to create UK clinical readiness. Her presentation elevated the profile of FSHD UK within the international research community.#FSHDUK
Last year, a @SciImmunology review highlighted the benefits of morning vaccination compared with afternoon/evening vaccination in humans.
Learn more: https://t.co/nI5xPxQo3V #DayOfImmunology
If you missed this week’s FORTITUDE webinar, you can watch the recording on our YouTube channel! Amy Halseth, PhD, and Alissa Peters of @aviditybio discussed the new FORTITUDE clinical trial that will test AOC 1020 in the treatment of #FSHD: https://t.co/NN0iSMy6Y4 #CureFSHD